150 related articles for article (PubMed ID: 17270028)
1. Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer.
Sakuma M; Akahira J; Ito K; Niikura H; Moriya T; Okamura K; Sasano H; Yaegashi N
Cancer Sci; 2007 Mar; 98(3):380-6. PubMed ID: 17270028
[TBL] [Abstract][Full Text] [Related]
2. Promoter methylation of cyclin D2 gene in gastric carcinoma.
Oshimo Y; Nakayama H; Ito R; Kitadai Y; Yoshida K; Chayama K; Yasui W
Int J Oncol; 2003 Dec; 23(6):1663-70. PubMed ID: 14612939
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers.
Virmani A; Rathi A; Heda S; Sugio K; Lewis C; Tonk V; Takahashi T; Roth JA; Minna JD; Euhus DM; Gazdar AF
Int J Cancer; 2003 Nov; 107(3):341-5. PubMed ID: 14506731
[TBL] [Abstract][Full Text] [Related]
5. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues.
Matsubayashi H; Sato N; Fukushima N; Yeo CJ; Walter KM; Brune K; Sahin F; Hruban RH; Goggins M
Clin Cancer Res; 2003 Apr; 9(4):1446-52. PubMed ID: 12684418
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.
Chou JL; Su HY; Chen LY; Liao YP; Hartman-Frey C; Lai YH; Yang HW; Deatherage DE; Kuo CT; Huang YW; Yan PS; Hsiao SH; Tai CK; Lin HJ; Davuluri RV; Chao TK; Nephew KP; Huang TH; Lai HC; Chan MW
Lab Invest; 2010 Mar; 90(3):414-25. PubMed ID: 20065949
[TBL] [Abstract][Full Text] [Related]
7. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.
Evron E; Umbricht CB; Korz D; Raman V; Loeb DM; Niranjan B; Buluwela L; Weitzman SA; Marks J; Sukumar S
Cancer Res; 2001 Mar; 61(6):2782-7. PubMed ID: 11289162
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation.
Akahira J; Sugihashi Y; Suzuki T; Ito K; Niikura H; Moriya T; Nitta M; Okamura H; Inoue S; Sasano H; Okamura K; Yaegashi N
Clin Cancer Res; 2004 Apr; 10(8):2687-93. PubMed ID: 15102672
[TBL] [Abstract][Full Text] [Related]
9. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers.
Takada T; Yagi Y; Maekita T; Imura M; Nakagawa S; Tsao SW; Miyamoto K; Yoshino O; Yasugi T; Taketani Y; Ushijima T
Cancer Sci; 2004 Sep; 95(9):741-4. PubMed ID: 15471560
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343
[TBL] [Abstract][Full Text] [Related]
11. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
12. Aberrant promoter methylation of SPARC in ovarian cancer.
Socha MJ; Said N; Dai Y; Kwong J; Ramalingam P; Trieu V; Desai N; Mok SC; Motamed K
Neoplasia; 2009 Feb; 11(2):126-35. PubMed ID: 19177197
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation status and expression of TMS1 gene in human epithelial ovarian cancer.
Akahira J; Sugihashi Y; Ito K; Niikura H; Okamura K; Yaegashi N
Cancer Sci; 2004 Jan; 95(1):40-3. PubMed ID: 14720325
[TBL] [Abstract][Full Text] [Related]
14. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin.
Dhillon VS; Shahid M; Husain SA
Mol Cancer; 2004 Dec; 3():33. PubMed ID: 15574200
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D2 expression in familial and sporadic breast cancer.
Fischer H; Chen J; Skoog L; Lindblom A
Oncol Rep; 2002; 9(6):1157-61. PubMed ID: 12375011
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
17. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X
Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
Wang Z; Li M; Lu S; Zhang Y; Wang H
Cancer Biol Ther; 2006 Mar; 5(3):256-60. PubMed ID: 16418574
[TBL] [Abstract][Full Text] [Related]
19. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
20. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers.
Zou B; Chim CS; Zeng H; Leung SY; Yang Y; Tu SP; Lin MC; Wang J; He H; Jiang SH; Sun YW; Yu LF; Yuen ST; Kung HF; Wong BC
Gastroenterology; 2006 Dec; 131(6):1835-43. PubMed ID: 17087954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
